Karyopharm Therapeutics (KPTI) Misses Q1 EPS by 251c

Karyopharm Therapeutics (NASDAQ: KPTI) reported Q1 EPS of ($2.77), $2.51 worse than the analyst estimate of ($0.26). Revenue for the quarter came in at $30.01 million versus the consensus estimate of $37.84 million.

For earnings history and earnings-related data on Karyopharm Therapeutics (KPTI) click here.

You May Also Be Interested In

• AstraZeneca's camizestrant fails primary endpoint in breast cancer trial
• Trilogy Metals closes $35.6M investment from U.S. Department of War
• Northrop Grumman wins two U.S. defense contracts worth $38.7m